Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Avenue Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 14 | 15 | +1 |
| Shares | 222.7K | 324.8K | +102.1K (+45.8%) |
| Value | $157.3K | $52.4K | −$104.8K (−66.7%) |
New holders (5)
Institutions that held Avenue Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 88,645 | $14.4K | 0.00% |
| Millennium Management LLC | 28,605 | $4.65K | 0.00% |
| HRT Financial LP | 25,283 | $4.00K | 0.00% |
| Cubist Systematic Strategies, LLC | 10,909 | $1.76K | 0.00% |
| UBS Group AG | 1,080 | $174 | 0.00% |
Sold out (4)
Institutions that held Avenue Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Bank of New York Mellon Corp | 51,572 | $36.5K |
| Shikiar Asset Management Inc | 12,500 | $9.00K |
| Advisor Group Holdings, Inc. | 500 | $353 |
| Morgan Stanley | 276 | $195 |